The roles of TRIO and F-actin-binding protein in glioblastoma cells

• Published in: Molecular medicine reports Vol. 17; no. 3; pp. 4540 - 4546
• Main Authors: Lee, Hyunji, Kim, Minhee, Park, Jisoo, Tran, Quangdon, Hong, Youngeun, Cho, Hyeonjeong, Park, Sungjin, Hong, Suntaek, Brazil, Derek P, Kim, Seon-Hwan, Park, Jongsun
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.03.2018; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Actin; Angiogenesis; Binding proteins; Brain cancer; Cancer therapies; Care and treatment; Cerebral cortex; Chemotherapy; Development and progression; Fluorides; Gene expression; Genetic aspects; Glioblastoma; Glioblastoma cells; Glioblastomas; Glioma; Health aspects; Hearing loss; Immunoglobulins; Kinases; Localization; Medical prognosis; Mutation; Patients; Proteins; Radiation therapy; Studies; Surgery; United States > US
• ISSN: 1791-2997; 1791-3004
• DOI: 10.3892/mmr.2018.8458

TRIO and F-actin-binding protein (TrioBP), which was initially discovered as a binding partner of Trio and F‑actin, is a critical factor associated with hearing loss in humans. However, the function of TrioBP in cancer has not been investigated. In the present study, TrioBP expression was indicated to be highly elevated in U87‑MG and U343‑MG cells. Furthermore, the TrioBP mRNA expression level was markedly increased in U87‑MG and U251‑MG cells compared with that in cerebral cortex cells, as determined by deep sequencing. Comprehensive analysis of a public TCGA dataset confirmed that TrioBP expression is elevated in patients with glioblastoma. In summary, the present data indicate that TrioBP expression is increased in glioblastoma cell lines and in patients with glioma, suggesting that TrioBP has potential as a diagnostic marker or therapeutic agent for glioma.